Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.53 |
| ▸ | MMP2 | P08253 | 8/20 | 0.53 |
| ▸ | MMP14 | P50281 | 4/20 | 0.53 |
| ▸ | MMP1 | P03956 | 3/20 | 0.53 |
| ▸ | MMP9 | P14780 | 3/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.53 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.53 |
| ▸ | MMP13 | P45452 | 2/20 | 0.53 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.53 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7163404 | 0.80 | MMP2 (0.62) | MMP2MMP14MMP1ADAMTS4MMP13 | |
| SCHEMBL7669130 | 0.77 | SGMS2 (0.67) | SGMS2MAPTGAA | |
| SCHEMBL7168984 | 0.76 | KAT6A (0.58) | MMP2MMP14MMP1ADAMTS4MMP13 | |
| SCHEMBL8048075 | 0.73 | MMP2 (0.65) | MMP2MMP14MMP1ADAMTS4MMP13 | |
| SCHEMBL6557782 | 0.72 | MMP2 (0.64) | MMP2MMP14MMP1MMP9ADAM17 | |
| SCHEMBL7675460 | 0.71 | SGMS2 (0.58) | SGMS2LMNAMAPTGAA | |
| SCHEMBL5934588 | 0.71 | CTSK (0.63) | MMP13CA1CTSKCTSS | |
| SCHEMBL974381 | 0.70 | SGMS2 (0.72) | SGMS2LMNAMAPTL3MBTL1NPC1 | |
| SCHEMBL3018273 | 0.70 | SGMS2 (0.76) | SGMS2LMNAMAPTL3MBTL1NPC1 | |
| SCHEMBL7247467 | 0.70 | MMP2 (0.72) | MMP2MMP14MMP1MMP9ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586466-B2 | Enzyme inhibitor for use in the treatment of bone, oral, arthritic, paget's and hypercalcemic diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-6562842-B2 | Osteoporosis, oral diseases | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| US-20020173469-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-20020077455-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-20 | — | — | US | disclosed |
| US-6331542-B1 | TREATING DISEASES CHARACTERIZED BY BONE LOSS OR EXCESSIVE CARTILAGE OR MATRIX DEGRADATION | SMITHKLINE BEECHAM CORPORATION | 2001-12-18 | — | — | US | disclosed |
| US-6284777-B1 | BONE DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-09-04 | — | — | US | disclosed |
| US-6232342-B1 | CATHEPSIN K INHIBITOR FOR TREATING OSTEOPOROSIS, GINGIVITIS, PERIODONTITIS, ARTHRITIS, OSTEOARTHRITIS RHEUMATOID ARTHRITIS, PAGET'S DISEASE, HYPERCALCEMIA OF MALIGNANCY AND METABOLIC BONE DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-05-15 | — | — | US | disclosed |
| US-6057362-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-5998470-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173469-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | SGMS2 3961/4885MMP2 26/4885MMP14 15/4885 |
| US-20020077455-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | SGMS2 3961/4885MMP2 26/4885MMP14 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.